The misuse of prescription opioids: A threat for Europe?

Current Drug Abuse Reviews

Volumn 8, Issue 1, 2015, Pages 3-14

  van Amsterdam, Jan ^a   van den Brink, Wim ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Diversion; Heroin; Misuse; Nonmedical use; Opioid dependence; Opioids; Oxycodone; Oxycontin; Pain relief; Prescription opioids

Indexed keywords

COCAINE; DIAMORPHINE; HYDROCODONE; METHADONE; MORPHINE; OPIATE; OXYCODONE; PRESCRIPTION DRUG; NARCOTIC ANALGESIC AGENT;

ALERTNESS; ANALGESIA; ARTICLE; DRUG MISUSE; EUROPE; HUMAN; MORBIDITY; MORTALITY; OPIATE ADDICTION; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH; DRUG OVERDOSE; OPIOID-RELATED DISORDERS; PAIN; STATISTICS AND NUMERICAL DATA;

ANALGESICS, OPIOID; DRUG OVERDOSE; EUROPE; HUMANS; OPIOID-RELATED DISORDERS; OXYCODONE; PAIN; PRESCRIPTION DRUG MISUSE; PREVALENCE;

EID: 84934759263     PISSN: 18744737     EISSN: 18744745     Source Type: Journal    
DOI: 10.2174/187447370801150611184218     Document Type: Article

References (115)

1. Manchikanti L, Helm S, Fellows B, et al. Opioid epidemic in the United States. Pain Physician 2012; 15: ES9-38.
2. Van Zee A. The promotion and marketing of oxycontin: commercial triumph, public health tragedy. Am J Public Health 2009; 99: 221-227.
3. Cicero TJ, Inciardi JA, Munoz A. Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004. J Pain 2005; 6: 662-672.
4. Okie S. A flood of opioids, a rising tide of deaths. N Engl J Med 2010; 363: 1981-1985.
5. Manchikanti L, Fellows B, Ailinani H, Pampati V. Therapeutic use, abuse, and nonmedical use of opioids: a ten-year perspective. Pain Physician 2010; 13: 401-435.
6. SAMHSA. Substance Abuse and Mental Health Services Administration (SAMHSA). Overview of findings from the 2004 National Survey on Drug Use and Health. Office of Applied Studies, NSDUH Series H-27, DHHS Publication No SMA 05-0461 Rockville, MD. 2005.
7. Volkow ND. Prescription Opioid and Heroin Abuse. http://www. drugabuse. gov/about-nida/legislativeactivities/testimony-to-congress/2014/prescription-opioid-heroinabuse. 2014.
8. Fischer B, Jones W, Rehm J. Trends and changes in prescription opioid analgesic dispensing in Canada 2005-2012: an update with a focus on recent interventions. BMC Health Serv Res 2014; 14: 90.
9. INCB. International Narcotics Control Board (INCB) Narcotic drugs technical report: Estimated world requirements for 2014-statistics for 2012 (No. T. 14. XI. 2). New York. 2014.
10. Fischer B, Gooch J, Goldman B, Kurdyak P, Rehm J. Non-medical prescription opioid use, prescription opioid-related harms and public health in Canada: an update 5 years later. Can J Public Health 2014; 105: e146-e149.
11. Lalomiteanu A, Adlaf EM, Hamilton H, Mann RE. CAMH Monitor eReport: Addiction and Mental Health Indicators Among Ontario Adults 1977-2011 (CAMH Research Document Series no. 40). Toronto: Centre for Addiction and Mental Health (CAMH). 2012. http://www. camh. ca/en/research/news_and_publications/CA MH%20Monitor/CAMH_Monitor_eReport_2013_Final. pdf. 2014.
12. Dasgupta N, Kramer ED, Zalman MA, Carino S Jr, Smith MY, Haddox JD et al. Association between non-medical and prescriptive usage of opioids. Drug Alcohol Depend 2006; 82: 135-142.
13. Gilson AM, Ryan KM, Joranson DE, Dahl JL. A reassessment of trends in the medical use and abuse of opioid analgesics and implications for diversion control: 1997-2002. J Pain Symptom Manage 2004; 28: 176-188.
14. Zacny J, Bigelow G, Compton P, Foley K, Iguchi M, Sannerud C. College on Problems of Drug Dependence taskforce on prescription opioid non-medical use and abuse: position statement. Drug Alcohol Depend 2003; 69: 215-232.
15. Imtiaz S, Shield KD, Fischer B, Rehm J. Harms of prescription opioid use in the United States. Subst Abuse Treat Prev Policy 2014; 9: 43.
16. SAMHSA. Substance Abuse and Mental Health Services Administration (SAMSA). Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings. NSDUH Series H-41, HHS Publication No. (SMA) 11-4658. Substance Abuse and Mental Health Services Administration, Rockville, MD, 2011. http://www. oas. samhsa. gov/NSDUH/2k10NSDUH/2k10Res ults. pdf. 2011.
17. Jones CM. Frequency of prescription pain reliever nonmedical use: 2002-2003 and 2009-2010. Arch Intern Med 2012; 172: 1265-1267.
18. SAMHSA. Substance Abuse and Mental Health Services Administration (SAMHSA). Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-48, HHS Publication No. (SMA) 14-4863. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2014. http://www. samhsa. gov/data/sites/default/fil es/NSDUHresultsPDFWHTML2013/Web/NSDUHresults2013. pdf. 2014.
19. CDC. CDC. U. S. Department of Health and Human Services. Addressing Prescription Drug Abuse in the United States. Current Activities and Future Opportunities. http://www. cdc. gov/Homeand RecreationalSafety/pdf/HHS_Prescription_Drug_Abuse_Report_09. 2013. pdf. 2013.
20. Catalano RF, White HR, Fleming CB, Haggerty KP. Is nonmedical prescription opiate use a unique form of illicit drug use? Addict Behav 2011; 36: 79-86.
21. CADUMS. Canadian Alcohol and Drug Use Monitoring Survey (CADUMS). http://www. hc-sc. gc. ca/hc-ps/drugs-drogues/stat/_20 12/summary-sommaire-eng. php. 2012.
22. CADUMS. Canadian Alcohol and Drug Use Monitoring Survey (CADUMS). http://www. hc-sc. gc. ca/hc-ps/drugs-drogues/stat/_20 08/summary-sommaire-eng. php. 2008.
23. Health Canada. Health Canada. Canadian alcohol and drug use monitoring survey 2008. http://data. library. utoronto. ca/datapub/c odebooks/cstdli/cadums/2008/cadums-technical-guide-2008-finaleng. pdf. 2008.
24. Dart RC, Surratt HL, Cicero TJ, Parrino MW, Severtson SG, Bucher-Bartelson B, et al. Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med 2015; 372: 241-248.
25. Compton WM, Volkow ND. Major increases in opioid analgesic abuse in the United States: concerns and strategies. Drug Alcohol Depend 2006; 81: 103-107.
26. Boudreau D, Von KM, Rutter CM, Saunders K, Ray GT, Sullivan MD et al. Trends in long-term opioid therapy for chronic noncancer pain. Pharmacoepidemiol Drug Saf 2009; 18: 1166-1175.
27. Manchikanti L. Prescription drug abuse: what is being done to address this new drug epidemic? Testimony before the Subcommittee on Criminal Justice, Drug Policy and Human Resources. Pain Physician 2006; 9: 287-321.
28. Wightman R, Perrone J, Portelli I, Nelson L. Likeability and abuse liability of commonly prescribed opioids. J Med Toxicol 2012; 8: 335-340.
29. Fischer B, Rehm J, Patra J, Cruz MF. Changes in illicit opioid use across Canada. CMAJ 2006; 175: 1385.
30. Cicero TJ, Ellis MS, Surratt HL. Effect of abuse-deterrent formulation of OxyContin. N Engl J Med 2012; 367: 187-189.
31. Daniulaityte R, Falck R, Carlson RG. Sources of pharmaceutical opioids for non-medical use among young adults. J Psychoactive Drugs 2014; 46: 198-207.
32. Zacny JP, Lichtor SA. Nonmedical use of prescription opioids: motive and ubiquity issues. J Pain 2008; 9: 473-486.
33. Boyd CJ, McCabe SE, Cranford JA, Young A. Adolescents' motivations to abuse prescription medications. Pediatrics 2006; 118: 2472-2480.
34. McCabe SE, Cranford JA, Boyd CJ, Teter CJ. Motives, diversion and routes of administration associated with nonmedical use of prescription opioids. Addict Behav 2007; 32: 562-575.
35. Sullivan MD, Edlund MJ, Zhang L, Unutzer J, Wells KB. Association between mental health disorders, problem drug use, and regular prescription opioid use. Arch Intern Med 2006; 166: 2087-2093.
36. Turk DC, Swanson KS, Gatchel RJ. Predicting opioid misuse by chronic pain patients: a systematic review and literature synthesis. Clin J Pain 2008; 24: 497-508.
37. Dowling K, Storr CL, Chilcoat HD. Potential influences on initiation and persistence of extramedical prescription pain reliever use in the US population. Clin J Pain 2006; 22: 776-783.
38. Winstock AR, Borschmann R, Bell J. The non-medical use of tramadol in the UK: findings from a large community sample. Int J Clin Pract 2014; 68: 1147-1151.
39. McCabe SE, West BT, Boyd CJ. Motives for medical misuse of prescription opioids among adolescents. J Pain 2013; 14: 1208-1216.
40. McCabe SE, Boyd CJ, Cranford JA, Teter CJ. Motives for nonmedical use of prescription opioids among high school seniors in the United States: self-treatment and beyond. Arch Pediatr Adolesc Med 2009; 163: 739-744.
41. McCabe SE, Cranford JA. Motivational subtypes of nonmedical use of prescription medications: results from a national study. J Adolesc Health 2012; 51: 445-452.
42. Havens JR, Walker R, Leukefeld CG. Prevalence of opioid analgesic injection among rural nonmedical opioid analgesic users. Drug Alcohol Depend 2007; 87: 98-102.
43. Wu LT, Woody GE, Yang C, Blazer DG. How do prescription opioid users differ from users of heroin or other drugs in psychopathology: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Addict Med 2011; 5: 28-35.
44. Fishbain DA, Cole B, Lewis J, Rosomoff HL, Rosomoff RS. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med 2008; 9: 444-459.
45. Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA 2013; 309: 657-659.
46. CDC. Centers for Disease Control and Prevention (CDC). CDC's top ten: 5 health achievements in 2013 and 5 health threats in 2014. http://blogs. cdc. gov/cdcworksforyou24-7/2013/12/cdc%E2%80%99s-top-ten-5-health-achievements-in-2013-and-5-health-threats-in-2014/. 2013.
47. Paulozzi LJ, Jones C, Mack K, Rudd R. Centers for Disease Control and Prevention (CDC). Vital signs: overdoses of prescription opioid pain relievers-United States, 1999-2008. MMWR Morb Mortal Wkly Rep 2011; 60: 1487-1492.
48. CDC. Centers for Disease Control and Prevention (CDC), Vital Signs: Overdoses of Prescription Opioid Pain Relievers-United States, 1999-2008, http://www. cdc. gov/mmwr/preview/mmwrhtm l/mm6043a4. htm. MMWR Morb Mortal Wkly Rep 2011; 60: 1487-1492.
49. Johnson H, Paulozzi L, Porucznik C, Mack K, Herter B. Decline in drug overdose deaths after state policy changes-Florida, 2010-2012. MMWR Morb Mortal Wkly Rep 2014; 63: 569-574.
50. CDC. Center for Disease Control and Prevention (CDC). Drug overdose deaths-Florida, 2003-2009. MMWR Morb Mortal Wkly Rep 2011; 60: 869-872.
51. CDC. CDC, National Center for Health Statistics. Multiple causes of death 1999-2010 on CDC WONDER Online database, released 2012. http://www. whitehouse. gov/sites/default/files/ondcp/Fact_Sheets/o pioids_fact_sheet. pdf. 2012.
52. DATIS. Drug and Alcohol Treatment Information System (DATIS). Substance Abuse StatisticalTables: Fiscal Year 2007/2008 to Fiscal Year 2011/2012. Toronto, ON: Centre for Addiction & Mental Health. 2012.
53. Fischer B, Argento E. Prescription opioid related misuse, harms, diversion and interventions in Canada: a review. Pain Physician 2012; 15: ES191-ES203.
54. Madadi P, Hildebrandt D, Lauwers AE, Koren G. Characteristics of opioid-users whose death was related to opioid-toxicity: a population-based study in Ontario, Canada. PLoS One 2013; 8: e60600.
55. Dhalla IA, Mamdani MM, Sivilotti ML, Kopp A, Qureshi O, Juurlink DN. Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. CMAJ 2009; 181: 891-896.
56. Gwira Baumblatt JA, Wiedeman C, Dunn JR, Schaffner W, Paulozzi LJ, Jones TF. High-risk use by patients prescribed opioids for pain and its role in overdose deaths. JAMA Intern Med 2014; 174: 796-801.
57. Hall AJ, Logan JE, Toblin RL, Kaplan JA, Kraner JC, Bixler D et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA 2008; 300: 2613-2620.
58. Lanier WA, Johnson EM, Rolfs RT, Friedrichs MD, Grey TC. Risk factors for prescription opioid-related death, Utah, 2008-2009. Pain Med 2012; 13: 1580-1589.
59. Johnson EM, Lanier WA, Merrill RM, Crook J, Porucznik CA, Rolfs RT et al. Unintentional prescription opioid-related overdose deaths: description of decedents by next of kin or best contact, Utah, 2008-2009. J Gen Intern Med 2013; 28: 522-529.
60. Gomes T, Mamdani MM, Dhalla IA, Paterson JM, Juurlink DN. Opioid dose and drug-related mortality in patients with nonmalignant pain. Arch Intern Med 2011; 171: 686-691.
61. Dunn KM, Saunders KW, Rutter CM, Banta-Green CJ, Merrill JO, Sullivan MD et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med 2010; 152: 85-92.
62. Bohnert AS, Valenstein M, Bair MJ, Ganoczy D, McCarthy JF, Ilgen MA et al. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA 2011; 305: 1315-1321.
63. Paulozzi LJ, Ryan GW. Opioid analgesics and rates of fatal drug poisoning in the United States. Am J Prev Med 2006; 31: 506-511.
64. Warner M. Trends in Drug-poisoning Deaths Involving Opioid Analgesics and Heroin: United States, 1999-2012. http://www. cdc. gov/nchs/data/hestat/drug_poisoning/drug_poisoning. htm. 2015.
65. CDC. Centers for Disease Control and Prevention (CDC). National Vital Statistics System mortality data. http://www. cdc. gov/nchs/deaths. htm. 2015.
66. SAMHSA. Highlights of the 2011 Drug Abuse Warning Network (DAWN) Findings on Drug-Related Emergency Department Visits. http://archive. samhsa. gov/data/2k13/DAWN127/sr127-DAWNhighlights. htm. 2013.
67. CDC. Center for Disease Control and Prevention (CDC). Emergency department visits involving nonmedical use of selected prescription drugs-United States, 2004-2008. MMWR Morb Mortal Wkly Rep 2010; 59: 705-709.
68. Macias A. State legislatures attempt to shut down the pill mills. Bull Am Coll Surg 2011; 96: 38-39.
69. Raffa RB, Pergolizzi JV, Jr. Opioid formulations designed to resist/deter abuse. Drugs 2010; 70: 1657-1675.
70. FDA. Food and Drug Administration (FDA). FDA announces safety labeling changes and postmarketing study requirements for extended-release and long-acting opioid analgesics (September 10, 2013). www. fda. gov/newsevents/newsroom/pressannouncements/u cm367726. htm. 2013.
71. Islam MM, McRae IS. An inevitable wave of prescription drug monitoring programs in the context of prescription opioids: pros, cons and tensions. BMC Pharmacol Toxicol 2014; 15: 46.
72. Degenhardt L, Dierker L, Chiu WT, Medina-Mora ME, Neumark Y, Sampson N et al. Evaluating the drug use "gateway" theory using cross-national data: consistency and associations of the order of initiation of drug use among participants in the WHO World Mental Health Surveys. Drug Alcohol Depend 2010; 108: 84-97.
73. Mars SG, Bourgois P, Karandinos G, Montero F, Ciccarone D. "Every 'never' I ever said came true": transitions from opioid pills to heroin injecting. Int J Drug Policy 2014; 25: 257-266.
74. Lankenau SE, Teti M, Silva K, Jackson BJ, Harocopos A, Treese M. Initiation into prescription opioid misuse amongst young injection drug users. Int J Drug Policy 2012; 23: 37-44.
75. Lankenau SE, Teti M, Silva K, Bloom JJ, Harocopos A, Treese M. Patterns of prescription drug misuse among young injection drug users. J Urban Health 2012; 89: 1004-1016.
76. Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. The changing face of heroin use in the United States: a retrospective analysis of the past 50 years. JAMA Psychiatry 2014; 71: 821-826.
77. Daniulaityte R, Carlson RG, Kenne DR. Initiation into pharmaceuticalopioids and patterns of misuse: Preliminary qualitative findings obtained by the Ohio Substance Abuse Monitoring Network. Journal of Drug Issues 2006; 36: 787-809.
78. Inciardi JA, Surratt HL, Cicero TJ, Beard RA. Prescription opioid abuse and diversion in an urban community: the results of an ultrarapid assessment. Pain Med 2009; 10: 537-548.
79. Rudd RA, Paulozzi LJ, Bauer MJ, Burleson RW, Carlson RE, Dao D et al. Increases in heroin overdose deaths-28 States, 2010 to 2012. MMWR Morb Mortal Wkly Rep 2014; 63: 849-854.
80. SAMHSA. Associations of nonmedical pain reliever use and Initiation of heroin use in the United States. http://www. samh sa. gov/data/2k13/DataReview/DR006/nonmedical-painreliever-use-2013. htm. 2013.
81. Dasgupta N, Creppage K, Austin A, Ringwalt C, Sanford C, Proescholdbell SK. Observed transition from opioid analgesic deaths toward heroin. Drug Alcohol Depend 2014; 145: 238-241.
82. Fischer B, Keates A, Buhringer G, Reimer J, Rehm J. Non-medical use of prescription opioids and prescription opioid-related harms: why so markedly higher in North America compared to the rest of the world? Addiction 2014; 109: 177-181.
83. Hamunen K, Laitinen-Parkkonen P, Paakkari P, Breivik H, Gordh T, Jensen NH et al. What do different databases tell about the use of opioids in seven European countries in 2002? Eur J Pain 2008; 12: 705-715.
84. EMCDDA. European Monitoring Center Drugs and Drug Abuse (EMCDDA). European Drug Report 2013. http://www. emcdda. europa. eu/attachements. cfm/att_213154_EN_TDAT13001ENN1. p df. 2014.
85. Casati A, Sedefov R, Pfeiffer-Gerschel T. Misuse of medicines in the European Union: a systematic review of the literature. Eur Addict Res 2012; 18: 228-245.
86. Schubert I, Ihle P, Sabatowski R. Increase in opiate prescription in Germany between 2000 and 2010: a study based on insurance data. Dtsch Arztebl Int 2013; 110: 45-51.
87. Bandieri E, Chiarolanza A, Luppi M, Magrini N, Marata AM, Ripamonti C. Prescription of opioids in Italy: everything, but the morphine. Ann Oncol 2009; 20: 961-962.
88. Caraceni AT, Brunelli C, Rocco P, Minghetti P. Trends in opioid analgesics sales to community pharmacies and hospitals in Italy (2000-2010). Minerva Anestesiol 2013; 79: 906-914.
89. Garcia del PJ, Carvajal A, Viloria JM, Velasco A, Garcia dP, V. Trends in the consumption of opioid analgesics in Spain. Higher increases as fentanyl replaces morphine. Eur J Clin Pharmacol 2008; 64: 411-415.
90. Hamunen K, Paakkari P, Kalso E. Trends in opioid consumption in the Nordic countries 2002-2006. Eur J Pain 2009; 13: 954-962.
91. Fredheim OM, Skurtveit S, Breivik H, Borchgrevink PC. Increasing use of opioids from 2004 to 2007: Pharmaco-epidemiological data from a complete national prescription database in Norway. Eur J Pain 2010; 14: 289-294.
92. Poulsen KK, Andersen SE, Moreno SI, Glintborg D, Thirstrup S, Aagaard L. General practitioners' and hospital physicians' preference for morphine or oxycodone as first-time choice for a strong opioid: a National Register-based study. Basic Clin Pharmacol Toxicol 2013; 112: 110-115.
93. NHS. National Health Service (NHS). National Treatment Agency for Substance Misuse. Addiction to medicine: An investigation into the configuration and commissioning of treatment services to support those who develop problems with prescription-only or over-the-counter medicine. http://www. nta. nhs. uk/uploads/addictio ntomedicinesmay2011a. pdf. 2011.
94. DCAMC. Drug Control and Access to Medicines Consortium (DCAMC). Opioid consumption chart. http://ppsg-production. herok u. com/chart. 2012.
95. Weisberg DF, Becker WC, Fiellin DA, Stannard C. Prescription opioid misuse in the United States and the United Kingdom: Cautionary lessons. Int J Drug Policy 2014.
96. Zin CS, Chen LC, Knaggs RD. Changes in trends and pattern of strong opioid prescribing in primary care. Eur J Pain 2014; 18: 1343-1351.
97. Ruscitto A, Smith BH, Guthrie B. Changes in opioid and other analgesic use 1995-2010: Repeated cross-sectional analysis of dispensed prescribing for a large geographical population in Scotland. Eur J Pain 2014.
98. Al-Asmari AI, Anderson RA, Cooper GA. Oxycodone-related fatalities in the west of Scotland. J Anal Toxicol 2009; 33: 423-432.
99. Hawton K, Bergen H, Simkin S, Wells C, Kapur N, Gunnell D. Six-year follow-up of impact of co-proxamol withdrawal in England and Wales on prescribing and deaths: time-series study. PLoS Med 2012; 9: e1001213.
100. GIP. Drugs and Medical Devices Information Project (GIP). https://www. gipdatabank. nl/databank. asp. 2014.
101. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006; 10: 287-333.
102. Hakkinen M, Launiainen T, Vuori E, Ojanpera I. Benzodiazepines and alcohol are associated with cases of fatal buprenorphine poisoning. Eur J Clin Pharmacol 2012; 68: 301-309.
103. Hakkinen M, Launiainen T, Vuori E, Ojanpera I. Comparison of fatal poisonings by prescription opioids. Forensic Sci Int 2012; 222: 327-331.
104. ONS. Office of National Statistics. Deaths related to drug poisoning in England and Wales, 2012. http://www. ons. gov. uk/ons/rel/subnational-health3/deaths-related-to-drug-poisoning/englandand-wales-2013/stb-deaths-related-to-drug-poisoning-inengland-and-wales-2013. html. 2014.
105. NRS. National Records of Scotland (NRS). Table Y. Drug-related deaths, on the basis of the Office for National Statistics (ONS) 'wide' definition, by selected drugs reported, 2001-2011. http://www. gro-scotland. gov. uk/files2/stats/drugrelateddeaths/2011/drug-related-deaths2011. pdf. 2011.
106. Giraudon I, Lowitz K, Dargan PI, Wood DM, Dart RC. Prescription opioid abuse in the UK. Br J Clin Pharmacol 2013; 76: 823-824.
107. Strang J, Hall W, Hickman M, Bird SM. Impact of supervision of methadone consumption on deaths related to methadone overdose (1993-2008): analyses using OD4 index in England and Scotland. BMJ 2010; 341: c4851.
108. NDM. Nationale Drug Monitor (NDM). Jaarbericht 2013/2014. Trimbos Instituut, Utrecht. http://www. trimbos. nl/projecten-enonderzoek/nationale-drug-monitor. 2014.
109. Cherny NI, Baselga J, de CF, Radbruch L. Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Europe: a report from the ESMO/EAPC Opioid Policy Initiative. Ann Oncol 2010; 21: 615-626.
110. Weisberg D, Stannard C. Lost in translation? Learning from the opioid epidemic in the USA. Anaesthesia 2013; 68: 1215-1219.
111. Galvez R. Variable use of opioid pharmacotherapy for chronic noncancer pain in Europe: causes and consequences. J Pain Palliat Care Pharmacother 2009; 23: 346-356.
112. Morgan O, Griffiths C, Hickman M. Association between availability of heroin and methadone and fatal poisoning in England and Wales 1993-2004. Int J Epidemiol 2006; 35: 1579-1585.
113. UNODC. United Nations Office on Drugs and Crime (UNODC). World Drug Report 2012. United Nations publication, Sales No. E. 12. XI. 1. 2012.
114. Hay G, Gannon M, Casey J, Millar T. Estimates of the Prevalence of Opi-ate Use and/or Crack Cocaine Use, 2009/2010: Sweep 6 report. Home Office Online Report. http://www. nta. nhs. uk/factsprevalence. aspx. 2011.
115. SAMHSA. Substance Abuse and Mental Health Services Administration (SAMHSA). Centerfor behavioral health statistics and quality. The N-SSATS report: Trends in the use ofmethadone and buprenorphine at substance abuse treatment facilities: 2003-2011. Rockville, MD. 2013.